Resources for families living with autism.
Information is listed at the discretion of Anova. Please note this is a partial list of resources and does not purport to include all organizations serving people with autism. Inclusion of any research or organization does not imply endorsement, and omission does not imply disapproval. Information is gathered primarily from public sources and is not guaranteed to be accurate. To suggest additions, please email info@anovaeducation.org.
The Tapestry Study
Axial Therapeutics is evaluating the effect of a new treatment, AB-2004, to improve irritability symptoms in adolescents with autism over an 8-week treatment period. AB-2004 is designed to absorb substances produced by certain bacteria in the gut that may reach the brain resulting in characteristics of autism. AB-2004 was shown to be safe and well tolerated in a previous study involving adolescents on the autism spectrum. This trial is taking place at both our Marin and Westlake Village locations. Your child may be eligible if they are 13-17 years old, diagnosed with autism, and experience high levels of irritability. For more information or to see if someone you know may be a good fit for this trial, please visit www.theautismstudy.com and contact research@corticacare.com.
The Penguin Study
Acadia Pharmaceuticals is evaluating the efficacy of Pimavanserin, an investigational medication, to determine if it may treat irritability and other behaviors in children and adolescents with autism. This trial is taking place at both our Marin and Westlake Village locations. The study includes 6 weeks of treatment and an opportunity for a year-long open label extension if desired. Your child may be eligible if they are 5-17 years old, diagnosed with autism, experience high levels of irritability, and have limited exposure to antipsychotic medications. For more information or to see if someone you know may be a good fit for this trial, please visit www.penguinautismstudy.com and contact research@corticacare.com.
Yamo Study
Yamo Pharmaceuticals is researching a novel therapy targeting social communication challenges in autistic adolescents and young adults aged 12-21. This trial is taking place at our Marin location. The study includes two 12-week treatment periods with guaranteed exposure to the medication, L1-79. For more information, please visit www.yamopharma.com and contact research@corticacare.com.
Sensory Processing, Imaging, and Neurodevelopment (SPIN) Study
The SPIN study is an NIH-funded observational study, uniting University of California, San Francisco (UCSF) and Cortica Marin. This study combines a battery of cognitive, sensory, and motor assessments at Cortica with a brain MRI at UCSF to illuminate the neurological underpinnings of sensory processing challenges in children aged 8-12. We are approaching our final year of recruitment and are already seeing some incredible findings arising from the data. For more information, please contact research@corticacare.com.
